Olumiant improved pain, physical function and morning joint stiffness in rheumatoid arthritis in phase III post-hoc analyses. Eli Lilly
These results are being presented at the virtual Annual European Congress of Rheumatology (EULAR), June 2-5, 2021. In a post-hoc analysis of the Phase III RA-BEAM study , patients treated with Olumiant 4 mg saw greater improvements in pain relief and physical function, as well as reduced duration of morning joint stiffness, at 12 weeks compared to Humira and placebo. These differences in pain relief were not influenced by disease activity during treatment. In this analysis, improvements in fatigue with Olumiant 4 mg were greater than with placebo and similar to Humira after 12 weeks of treatment. Safety results were consistent with the established safety profile for Olumiant in patients with RA. Lilly will also present analyses from the prospective Swiss Clinical Quality Management (SCQM) observational cohort, a study that evaluated the effectiveness and persistence of OLumiant compared to other biologics for the treatment of RA.
Related news and insights
Pfizer Inc. announced that FDA approved Cibinqo (abrocitinib), an oral, once-daily, Janus kinase 1 (JAK1) inhibitor, for the treatment of adults living with refractory, moderate-to-severe atopic dermatitis (AD) whose disease is not adequately controlled with other systemic drug products, including biologics, or when use of those therapies is inadvisable.
Pfizer Inc. announced positive top-line results from a Phase III study (B7471026) describing the safety and immunogenicity of Prevnar 20 (Pneumococcal 20-valent Conjugate Vaccine) in 570 adults in the United States 65 years of age or older when administered at the same time as the Pfizer-BioNTech COVID-19 Vaccine or when each vaccine was given with placebo.
Roche announced the launch of the cobas pulse system in select countries accepting the CE Mark. The cobas pulse system marks Roche Diagnostics’ newest generation of connected point of care solutions for professional blood glucose management.